Long acting GLP-1 receptor agonist (injectable)
Liraglutide injection
LIRA_SC
Doses in this pooled treatment
- Liraglutide 1.8 mg subcutaneous once daily
- Liraglutide flexible dose injection once daily
- Liraglutide 3.0 mg subcutaneous once daily
- Liraglutide maximum tolerated dose injection once daily
- Liraglutide 0.9 mg injection once daily
- Liraglutide flexible dose injection once daily
- Liraglutide 1.2 mg subcutaneous once daily
- Liraglutide maximum tolerated dose injection once daily
- Liraglutide 0.6 mg subcutaneous once daily
- Liraglutide subcutaneous once daily, flexible dose: 1.2 or 1.8 mg by tolerability
- Liraglutide 2.4 mg injection once daily
- Liraglutide maximum tolerated dose injection once daily
- Liraglutide maximum tolerated dose injection once daily
- Liraglutide 0.6 mg injection
- Liraglutide 1.2 mg injection
- Liraglutide 1.25UG/KG injection once daily
- Liraglutide 5.0UG/KG injection once daily
- Liraglutide 7.5UG/KG injection once daily
- Liraglutide 10UG/KG injection once daily
- Liraglutide 12.5UG/KG injection once daily
- Liraglutide 0.3 mg injection once daily
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.07 (-1.48 to -0.65) | 0.67 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.99 (-1.15 to -0.80) | 0.64 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -0.24 (-0.88 to 0.47) | 0.49 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -0.79 (-1.35 to -0.11) | 0.54 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.08 (-1.60 to -0.27) | 0.64 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.85 (-1.48 to -0.19) | 0.58 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.47 (-4.30 to 1.34) | 0.58 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.11 (-1.72 to -0.51) | 0.76 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -1.23 (-1.95 to 0.06) | 0.63 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.16 (-1.65 to -0.40) | 0.71 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -2.09 (-3.22 to -0.99) | 0.64 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD -0.63 (-3.12 to 2.41) | 0.49 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -1.27 (-2.05 to -0.52) | 0.71 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD -2.07 (-4.61 to 0.76) | 0.49 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD 1.11 (-1.02 to 6.05) | 0.22 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -2.24 (-5.41 to 1.14) | 0.60 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD 1.59 (-2.37 to 6.40) | 0.37 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -3.07 (-7.54 to 1.40) | 0.76 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Dulaglutide injection | MD 0.06 (-4.92 to 5.10) | 0.40 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD 0.26 (-2.65 to 3.41) | 0.41 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 8.20 (2.71 to 18.56) | 0.53 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 36 to 64 (target week 52) | Semaglutide injection | OR 0.45 (0.18 to 1.49) | 0.39 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 36 to 64 (target week 52) | Placebo | OR 6.04 (1.45 to 16.71) | 0.72 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 36 to 64 (target week 52) | Placebo | OR 5.37 (1.11 to 15.73) | 0.69 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 3.42 (1.70 to 5.95) | 0.46 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 7.62 (1.67 to 20.83) | 0.64 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 12.76 (3.91 to 34.71) | 0.72 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 36 to 64 (target week 52) | Placebo | OR 4.57 (0.89 to 16.65) | 0.51 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.23 (0.05 to 0.76) | 0.54 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 2.46 (1.01 to 5.77) | 0.52 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.96 (0.53 to 1.69) | 0.74 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.92 (0.49 to 1.69) | 0.54 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -3.01 (-4.23 to -1.64) | 0.72 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD -1.20 (-4.06 to 2.39) | 0.70 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD -4.18 (-11.60 to 2.28) | 0.74 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD -2.93 (-11.58 to 6.00) | 0.64 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD -3.85 (-13.42 to 6.91) | 0.65 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -1.35 (-6.57 to 3.32) | 0.71 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -4.84 (-8.71 to -1.09) | 0.67 |
| Type 2 diabetes (adults) | Percent body weight change | weeks 40 to 104 (target week 68) | Semaglutide tablet | MD 2.15 (-4.77 to 8.90) | 0.29 |
| Type 2 diabetes (adults) | Percent body weight change | weeks 40 to 104 (target week 68) | Placebo | MD -2.23 (-6.08 to 2.03) | 0.58 |
| Type 2 diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -2.71 (-6.90 to 1.80) | 0.54 |
| Type 2 diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD 0.10 (-9.53 to 10.71) | 0.31 |
| Type 2 diabetes (adults) | Percent body weight change | weeks 40 to 104 (target week 68) | Placebo | MD -5.08 (-12.34 to 2.09) | 0.70 |
| Type 2 diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -1.80 (-5.53 to 2.17) | 0.42 |
| Type 2 diabetes (adults) | Percent body weight change | weeks 40 to 104 (target week 68) | Placebo | MD -1.16 (-5.92 to 5.65) | 0.50 |
| Type 2 diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD 1.26 (-3.64 to 6.41) | 0.16 |
| Type 2 diabetes (adults) | Weight loss of 5 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 5.00 (1.18 to 14.83) | 0.56 |
| Type 2 diabetes (adults) | Weight loss of 5 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 2.28 (0.68 to 6.16) | 0.60 |
| Type 2 diabetes (adults) | Weight loss of 5 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 4.55 (1.45 to 11.78) | 0.77 |
| Type 2 diabetes (adults) | Weight loss of 5 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 3.78 (0.93 to 11.80) | 0.69 |
| Type 2 diabetes (adults) | Weight loss of 5 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 2.14 (0.81 to 4.96) | 0.53 |
| Type 2 diabetes (adults) | Weight loss of 5 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 2.90 (0.82 to 7.48) | 0.36 |
| Type 2 diabetes (adults) | Weight loss of 5 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 1.86 (0.46 to 6.41) | 0.43 |
| Type 2 diabetes (adults) | Weight loss of 5 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 0.08 (0.00 to 0.85) | 0.01 |
| Type 2 diabetes (adults) | Weight loss of 10 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 5.68 (1.14 to 34.06) | 0.53 |
| Type 2 diabetes (adults) | Weight loss of 10 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 2.03 (0.52 to 9.03) | 0.61 |
| Type 2 diabetes (adults) | Weight loss of 10 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 4.43 (0.64 to 28.79) | 0.66 |
| Type 2 diabetes (adults) | Weight loss of 10 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 2.14 (0.62 to 7.76) | 0.58 |
| Type 2 diabetes (adults) | Weight loss of 10 percent or more | weeks 40 to 104 (target week 68) | Semaglutide injection | OR 0.26 (0.09 to 0.86) | 0.31 |
| Type 2 diabetes (adults) | Weight loss of 10 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 1.60 (0.26 to 9.21) | 0.21 |
| Type 2 diabetes (adults) | Weight loss of 10 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 0.40 (0.01 to 11.91) | 0.18 |
| Type 2 diabetes (adults) | Three point MACE | longest follow-up | Placebo | HR 0.95 (0.19 to 4.67) | 0.45 |
| Type 2 diabetes (adults) | SF-36 physical component summary change | weeks 20 to 130 (target week 52) | Placebo | MD 0.25 (-1.21 to 1.69) | 0.53 |
| Type 2 diabetes (adults) | SF-36 physical component summary change | weeks 20 to 130 (target week 52) | Placebo | MD 0.41 (-1.78 to 2.76) | 0.51 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.81 (0.68 to 0.96) | 0.69 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 1.96 (1.33 to 2.79) | 0.37 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 3.30 (2.68 to 4.12) | 0.32 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 2.78 (2.05 to 3.77) | 0.39 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.87 (1.56 to 2.24) | 0.35 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 1.89 (1.48 to 2.46) | 0.37 |
| Type 2 diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 3.89 (1.76 to 8.68) | 0.26 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.21 (0.04 to 0.83) | 0.74 |
| Type 2 diabetes (adults) | Diabetic retinopathy complications | longest follow-up | Placebo | HR 0.87 (0.19 to 3.88) | 0.63 |
| Type 2 diabetes (adults) | Pancreatic cancer | longest follow-up | Placebo | HR 1.70 (0.23 to 13.08) | 0.30 |
| Type 2 diabetes (adults) | Any cancer | longest follow-up | Placebo | HR 0.86 (0.13 to 4.79) | 0.67 |
| Overweight or obesity without diabetes (adults) | Systolic blood pressure change | weeks 20 to 40 (target week 26) | Placebo | MD -0.67 (-11.71 to 11.37) | 0.32 |
| Overweight or obesity without diabetes (adults) | Systolic blood pressure change | weeks 40 to 104 (target week 68) | Placebo | MD -3.85 (-6.00 to -1.84) | 0.50 |
| Overweight or obesity without diabetes (adults) | Systolic blood pressure change | weeks 20 to 40 (target week 26) | Placebo | MD -4.62 (-12.59 to 1.73) | 0.63 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -5.91 (-12.23 to 1.34) | 0.54 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 40 to 104 (target week 68) | Placebo | MD -5.41 (-7.58 to -3.25) | 0.40 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -5.16 (-9.81 to -0.42) | 0.44 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -5.33 (-11.99 to 1.94) | 0.48 |
| Overweight or obesity without diabetes (adults) | Weight loss of 5 percent or more | weeks 104 to 182 (target week 104) | Placebo | OR 0.36 (0.11 to 1.26) | 0.03 |
| Overweight or obesity without diabetes (adults) | Weight loss of 5 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 3.66 (1.35 to 9.58) | 0.43 |
| Overweight or obesity without diabetes (adults) | Weight loss of 10 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 2.00 (0.61 to 6.51) | 0.29 |
| Overweight or obesity without diabetes (adults) | Weight loss of 10 percent or more | weeks 104 to 182 (target week 104) | Placebo | OR 6.24 (1.46 to 25.38) | 0.64 |
| Overweight or obesity without diabetes (adults) | Weight loss of 10 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 13.31 (3.09 to 54.16) | 0.65 |
| Overweight or obesity without diabetes (adults) | Weight loss of 15 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 1.47 (0.56 to 4.07) | 0.26 |
| Overweight or obesity without diabetes (adults) | Weight loss of 20 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 1.59 (0.52 to 4.72) | 0.20 |
| Overweight or obesity without diabetes (adults) | SF-36 physical component summary change | weeks 20 to 130 (target week 52) | Placebo | MD 1.67 (-0.06 to 3.66) | 0.91 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.36 (0.97 to 1.88) | 0.48 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 3.43 (1.08 to 13.45) | 0.36 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 3.76 (3.13 to 4.59) | 0.46 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 4.06 (2.84 to 5.92) | 0.58 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.67 (1.24 to 2.24) | 0.58 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 2.60 (1.95 to 3.54) | 0.40 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 10.56 (0.99 to 253) | 0.19 |
| Overweight or obesity without diabetes (adults) | Gallbladder and biliary disease | longest follow-up | Placebo | HR 1.95 (0.10 to 38.66) | 0.48 |
| Children and adolescents with obesity | Percent body weight change | weeks 40 to 104 (target week 68) | Placebo | MD -3.82 (-8.44 to 2.41) | 0.91 |
| Children and adolescents with obesity | BMI standard deviation score change | weeks 40 to 104 (target week 68) | Placebo | MD -0.23 (-0.55 to 0.12) | 0.47 |
| Children and adolescents with obesity | Percent BMI change | weeks 40 to 104 (target week 68) | Placebo | MD -4.63 (-12.88 to 4.04) | 0.68 |
| Children and adolescents with obesity | Serious adverse events | longest follow-up | Placebo | HR 0.71 (0.15 to 3.46) | 0.72 |
| Children and adolescents with obesity | Nausea | longest follow-up | Placebo | HR 3.79 (1.52 to 10.96) | 0.16 |
| Children and adolescents with obesity | Vomiting | longest follow-up | Placebo | HR 10.48 (3.39 to 35.60) | 0.15 |
| Children and adolescents with obesity | Diarrhea | longest follow-up | Placebo | HR 1.70 (0.56 to 5.09) | 0.33 |
| Children and adolescents with obesity | Constipation | longest follow-up | Placebo | HR 5.00 (0.37 to 140) | 0.22 |
| Children and adolescents with type 2 diabetes | HbA1c change | weeks 12 to 40 (target week 26) | Standard care or no added treatment | MD 0.41 (-1.20 to 1.97) | 0.47 |
| Children and adolescents with type 2 diabetes | Serious adverse events | longest follow-up | Placebo | HR 2.13 (0.43 to 9.40) | 0.26 |
| Children and adolescents with type 2 diabetes | Nausea | longest follow-up | Placebo | HR 2.26 (0.60 to 7.43) | 0.29 |
| Children and adolescents with type 2 diabetes | Vomiting | longest follow-up | Placebo | HR 3.47 (0.88 to 14.40) | 0.33 |
| Children and adolescents with type 2 diabetes | Diarrhea | longest follow-up | Placebo | HR 1.45 (0.41 to 4.88) | 0.43 |
| Type 1 diabetes | HbA1c change | weeks 12 to 40 (target week 26) | Placebo | MD -0.05 (-0.50 to 0.53) | 0.35 |
| Type 1 diabetes | Total daily insulin dose change | weeks 12 to 40 (target week 26) | Placebo | MD 0.36 (-0.59 to 1.36) | 0.20 |
| Type 1 diabetes | Serious adverse events | longest follow-up | Placebo | HR 1.01 (0.48 to 2.11) | 0.48 |
| Type 1 diabetes | Nausea | longest follow-up | Placebo | HR 3.55 (1.74 to 6.64) | 0.01 |
| Type 1 diabetes | Vomiting | longest follow-up | Placebo | HR 2.75 (1.22 to 6.64) | 0.01 |
| Type 1 diabetes | Diarrhea | longest follow-up | Placebo | HR 1.37 (0.67 to 2.73) | 0.13 |
| Type 1 diabetes | Constipation | longest follow-up | Placebo | HR 2.09 (0.86 to 5.21) | 0.04 |
| Chronic kidney disease with diabetes | Serious adverse events | longest follow-up | Placebo | HR 0.91 (0.25 to 3.10) | 0.64 |
| Chronic kidney disease with diabetes | Nausea | longest follow-up | Placebo | HR 5.05 (1.16 to 17.91) | 0.23 |
| Chronic kidney disease with diabetes | Vomiting | longest follow-up | Placebo | HR 5.32 (1.11 to 25.67) | 0.36 |
| Chronic kidney disease with diabetes | Diarrhea | longest follow-up | Placebo | HR 2.34 (0.54 to 10.51) | 0.50 |
| Chronic kidney disease with diabetes | Constipation | longest follow-up | Placebo | HR 3.63 (0.67 to 22.45) | 0.27 |
| Polycystic ovary syndrome | Nausea | longest follow-up | Placebo | HR 6.88 (3.08 to 15.30) | 0.10 |
| Polycystic ovary syndrome | Vomiting | longest follow-up | Placebo | HR 6.79 (1.66 to 39.11) | 0.27 |
| Polycystic ovary syndrome | Diarrhea | longest follow-up | Placebo | HR 2.90 (0.92 to 10.94) | 0.25 |
| Polycystic ovary syndrome | Constipation | longest follow-up | Placebo | HR 9.40 (2.05 to 59.00) | 0.00 |
| Polycystic ovary syndrome | Regular menstrual cycles | weeks 12 to 52 (target week 26) | Standard care or no added treatment | OR 1.52 (0.25 to 9.64) | 0.45 |
Trials
- S00306819 randomized · 36 weeks
- S003425115 randomized · 13.04 weeks
- S00307060 randomized · 2 weeks
- S0030230.43 weeks
- S0034362023 · 150 randomized · 24 weeks
- NCT05268627Endoscopic Ultrasound Guided Gastric Botulinum Toxin Injections Versus Glucagon Like Peptide 1 Receptor Agonist in Weight Loss2021 · 40 randomized · 16 weeks
- NCT04969627Effects of GLP-1 Analogue Combined With Metformin and Metformin on Gonadal and Metabolic Profiles in Chinese Overweight/Obese PCOS Patients With Hyperandrogenemia.2021 · 60 randomized · 12 weeks
- NCT04311411Effect of Tirzepatide on Energy Intake and Appetite-and Reward-Related Brain Areas in Overweight/Obese Subjects: A Placebo-Controlled 6-Week Study With Functional MRI2020 · 114 randomized · 6 weeks
- S0034322020 · 218 randomized · 52 weeks
- S0031522019 · 360 randomized · 24 weeks
- S0031002019 · 90 randomized · 13.04 weeks
- NCT03856047Investigation of Safety and Efficacy of NNC0174-0833 for Weight Management - a Dose Finding Trial.2019 · 706 randomized · 26 weeks
- S0034272019 · 148 randomized · 52.14 weeks
- S0029702019 · 39 randomized · 26.07 weeks
- S0030172019 · 48 randomized · 52.14 weeks
- STEP 8Effect and Safety of Subcutaneous Semaglutide 2.4 mg Once Weekly Compared to Liraglutide 3.0 mg Once Daily on Weight Management in Subjects With Overweight or Obesity2019 · 338 randomized · 68 weeks
- S0034422019 · 96 randomized · 24 weeks
- S0030222018 · 60 randomized · 12 weeks
- S0029692018 · 27 randomized · 26 weeks
- NCT03555994An Exploratory Phase 2, Randomised, Double-blind, Placebo-controlled, and Open-label Active Comparator Study to Evaluate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.2018 · 51 randomized · 5 weeks
- SAXAPCOSA Randomized Placebo-controlled Double Blind Trial of Liraglutide 3 mg [Saxenda] on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With Polycystic Ovary Syndrome (PCOS)2018 · 82 randomized · 32 weeks
- BARIOPTIMISEBARI-OPTIMISE: a Double-blinded, Randomised, Placebo-controlled Trial of Liraglutide 3.0 mg in Patients With Poor Weight-loss and a Suboptimal Glucagon-like Peptide-1 Response Following Bariatric Surgery2018 · 70 randomized · 24 weeks
- LIRAFLAMEEffect of Liraglutide on Vascular Inflammation in Type-2 Diabetes: A Randomized, Placebo-controlled, Double-blind, Parallel Clinical PET/CT Trial The Liraflame Trial2017 · 102 randomized · 26 weeks
- NCT03101930Cardiovascular Effects of GLP-1 Receptor Activation2017 · 93 randomized · 14 weeks
- STRIVEEFFECTIVENESS AND COST OF INTEGRATING A PROTOCOL WITH USE OF LIRAGLUTIDE 3.0 MG INTO AN OBESITY SERVICE: (STRIVE Study)2017 · 392 randomized · 104 weeks
- NCT03151005Randomized Clinical Trial to Evaluate The Effect of Metformin-GLP-1 Receptor Agonist Versus Oral Contraceptive (OC) Therapy on Reproductive Disorders and Cardiovascular Risks in Overweight Polycystic Ovarian Syndrome (PCOS) Patients2017 · 70 randomized · 12 weeks
- SCALE™ InsulinEffect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin2017 · 396 randomized · 56 weeks
- NCT03523273Pilot Study of the Effect of Liraglutide 3.0 mg on Weight Loss and Gastric Functions in Obesity2017 · 136 randomized · 16 weeks
- NCT03235050A Phase IIb, Randomised, Parallel, Double-Blind Placebo-Controlled and Open-Label Active Comparator Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes Mellitus2017 · 834 randomized · 54 weeks
- NCT03041792A 6-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, TWO-ARM, PARALLEL METHODOLOGY STUDY TO ASSESS THE EFFECT OF LIRAGLUTIDE ON FOOD INTAKE IN OBESE SUBJECTS2017 · 61 randomized · 6 weeks
- SUSTAIN 10Efficacy and Safety of Semaglutide 1.0 mg Once-weekly Versus Liraglutide 1.2 mg Once-daily as add-on to 1-3 Oral Anti-diabetic Drugs (OADs) in Subjects With Type 2 Diabetes2017 · 577 randomized · 30 weeks
- NCT03878706The Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination on Endothelial Function, Arterial Stiffness and Left Ventricular Deformation in Patients With Type 2 Diabetes With High Cardiovascular Risk2017 · 180 randomized · 52.14 weeks
- DUAL™ I ChinaA Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)2017 · 720 randomized · 26 weeks
- NCT03038620Impact of Liraglutide 3.0 on Body Fat Distribution, Visceral Adiposity, and Cardiometabolic Risk Markers In Overweight and Obese Adults at High Risk for Cardiovascular Disease2017 · 40 weeks
- NCT02960659Therapeutic Targets in African-American Youth With Type 2 Diabetes2017 · 24 randomized · 12 weeks
- NCT02953665A Phase II, Randomized, Double-blinded, Placebo-controlled Trial of Liraglutide in Parkinson's Disease2017 · 63 randomized · 54 weeks
- PIONEER 9Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes2017 · 243 randomized · 52 weeks
- PIONEER 4Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus2016 · 711 randomized · 52 weeks
- NCT02696148A Randomised, Double-blind, Placebo-controlled Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Obese Children Aged 7 to 11 Years2016 · 24 randomized · 7 weeks
- NCT02918279Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity. 56-week, Double-blind, Randomised, Parallel-group, Placebo-controlled Multi-national Trial Followed by a 26-week Period Off Study-drug2016 · 251 randomized · 56 weeks
- S-LITESynergy Effect of the Appetite Hormone GLP-1 (LiragluTide) and Exercise on Maintenance of Weight Loss and Health After a Low Calorie Diet - the S-LiTE Randomized Trial2016 · 195 randomized · 52 weeks
- LIRA-PRIMEEfficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy and Treated in a Primary Care Setting2016 · 1,991 randomized · 104 weeks
- NCT02973321A 26-Week Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase 2 Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus2016 · 296 randomized · 26 weeks
- NCT02717858A Single-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Trial to Assess the Effects of Liraglutide on Gallbladder Emptying in Overweight and Obese Subjects2016 · 52 randomized · 12 weeks
- NCT02617654A Randomized, Double-blinded Placebo-controlled, Paralleled Designed, Investigator Sponsored Study of the Effect of the GLP-1 Receptor Agonist Liraglutide on Beta-cell Function in C-peptide Positive Type 1 Diabetic Patients2015 · 18 randomized · 52 weeks
- DUAL™ I JapanA Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus2015 · 819 randomized · 52 weeks
- NCT02505334A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus2015 · 466 randomized · 26 weeks
- NCT02909933Low Dose Liraglutide and Metformin vs. High Dose Liraglutide Alone in Treatment of Obesity2015 · 30 randomized · 12 weeks
- LIRAVISShort Term Effect of Liraglutide Versus Vildagliptine on Insulin Secretion and Insulin Sensitivity in a Sub Saharan African Population With Type 2 Diabetes2015 · 14 randomized · 2 weeks
- NCT02527200Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome.2015 · 56 randomized · 52 weeks
- NCT03010683Effects of Agonists of Glucagon Like Peptide - 1 Receptors (GLP-1R) on Arterial Stiffness, Endothelial Glycocalyx and Coronary Flow Reserve in Patients With Coronary Artery Disease and Patients With Diabetes Mellitus2015 · 60 randomized · 26.07 weeks
- NCT02765399The Effect of Liraglutide Treatment on Postprandial Chylomicron and VLDL Kinetics, Liver Fat and de Novo Lipogenesis - a Single-center Randomized Controlled Study2015 · 23 randomized · 16 weeks
- NCT02647944Pilot Study of the Effect of Liraglutide on Weight Loss and Gastric Functions in Obesity2015 · 40 randomized · 16 weeks
- MAGNA VICTORIAMagnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes Mellitus and South Asian Descent2015 · 47 randomized · 26 weeks
- NCT02453711Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus2015 · 957 randomized · 52 weeks
- NCT03068065Comparison of Efficacy of Liraglutide, Metformin and Gliclazide MR on Hepatic Lipid Content in Patients With Type 2 Diabetes (T2DM) and Non-alcoholic Fatty Liver (NAFLD)2014 · 93 randomized · 24 weeks
- NCT02490176Effects of Liraglutide on Hemodynamic Parameters in Patients With Heart Failure2014 · 52 randomized · 1 weeks
- ELADEvaluating the Effects of the Novel GLP-1 Analogue, Liraglutide, in Patients With Mild Alzheimer's Disease (ELAD Study)2014 · 204 randomized · 52 weeks
- LIPTA Randomised, Double-blind, Placebo-controlled Study of the Effect of Liraglutide in Polycystic Ovary Syndrome on Risk Markers of Vascular Thrombosis.2014 · 72 randomized · 26 weeks
- LIRA-Ramadan™Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes2014 · 343 randomized · 30 weeks
- NCT02324842Effect of Combined Incretin-Based Therapy Plus Canagliflozin on Glycemic Control and the Compensatory Rise in Hepatic Glucose Production in Type 2 Diabetic Patients2014 · 45 randomized · 16 weeks
- LIGHT-ONEfficacy of Liraglutide vs. Sitagliptin vs. Insulin Glargine Per Day on Liver Fat When Combined With Metformin in T2DM Subjects With Non-alcoholic Fatty-liver Disease2014 · 75 randomized · 26 weeks
- TODINELIA Randomized, Double-blinded, Single-centre, Parallel-group, Placebo-controlled, Prospective Trial of Neuroprotective Effect of Liraglutide for Treatment of Diabetic Neuropathy.2014 · 48 randomized · 26 weeks
- ADJUNCT TWO™A 26-weeks Randomised, Insulin Capped, Placebo-controlled, Double-blind, Parallel Group, Multinational, Multi-centre Trial2014 · 835 randomized · 26 weeks
- NCT02187250Short-term Treatment With PDE-4 Inhibitor Roflumilast or GLP-1 Agonist Liraglutide or Metformin in Treatment Naive Obese Women With Polycystic Ovary Syndrome2014 · 45 randomized · 12 weeks
- SIMPLEThe Effect of Simple Insulin Detemir Titration, Metformin Plus Liraglutide Compared to Simple Insulin Detemir Titration Plus Insulin Aspart and Metformin for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study: A 26 Week, Randomized, Open Label, Parallel-group, Intention to Treat Study2014 · 120 randomized · 26 weeks
- S0029042014 · 120 randomized · 24 weeks
- S0030412014 · 35 randomized · 2 weeks
- S0031012014 · 72 randomized · 26 weeks
- ADJUNCT ONE™The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial2013 · 1,398 randomized · 52 weeks
- NCT02008682The Efficacy and Safety of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes.(LIRA-DPP-4 CHINA™)2013 · 368 randomized · 26 weeks
- LIRA-SWITCH™Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin2013 · 407 randomized · 26 weeks
- GRADEGlycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study2013 · 5,047 randomized · 365.26 weeks
- NCT02059564A Phase 1b, Exploratory, Randomized, Partially Single Blinded, Placebo and Open Label Controlled, Parallel Group Study to Assess the Effects of HM11260C and an Active Comparator on Gastric Emptying and Beta-Cell Response in Subjects With Type 2 Diabetes Mellitus2013 · 47 randomized · 13 weeks
- RISE AdultRestoring Insulin Secretion Adult Medication Study2013 · 267 randomized · 52.14 weeks
- S0030062013 · 60 randomized · 24 weeks
- NCT01733758A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Monotherapy Study to Determine the Efficacy and Safety of 2 Dose Levels of Albiglutide in Subjects With Type 2 Diabetes Mellitus2013 · 494 randomized · 52 weeks
- NCT02113332Addition of Liraglutide to Overweight Patients With Type 2 Diabetes Treated With Multiple Daily Insulin Injections (MDI) With Inadequate Glycaemic Control2013 · 124 randomized · 24 weeks
- NCT01425580Effects on Subclinical Heart Failure in Type 2 Diabetic Subjects on Liraglutide Treatment Versus Glimepiride Both in Combination With Metformin2012 · 62 randomized · 18 weeks
- NCT01795248The Impact of Liraglutide on Glucose Tolerance and the Risk of Type 2 Diabetes in Women With Previous Gestational Diabetes Mellitus2012 · 104 randomized · 52 weeks
- Ellipse™Efficacy and Safety of Liraglutide in Combination With Metformin Versus Metformin Monotherapy on Glycaemic Control in Children and Adolescents With Type 2 Diabetes2012 · 135 randomized · 52 weeks
- AWARD-6A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-Weekly Dulaglutide With Once-Daily Liraglutide in Patients With Type 2 Diabetes (AWARD-6: Assessment of Weekly AdministRation of LY2189265 in Diabetes-6)2012 · 599 randomized · 26 weeks
- NCT01557166Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea. A 32 Week Randomised, Double-blind, Placebo-controlled, Parallel Group, Multi-centre and Multinational Trial2012 · 359 randomized · 32 weeks
- NCT01617434The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes2012 · 451 randomized · 26 weeks
- NCT01558271A Phase 3 Study of LY2189265 Monotherapy Compared to Placebo and Liraglutide in Patients With Type 2 Diabetes Mellitus2012 · 492 randomized · 52 weeks
- S0031082012 · 24 weeks
- NCT01620489Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment. A 26-week Double-blind Placebo-controlled, Randomised, Multicentre, Multi-national, Parallel-group Trial2012 · 279 randomized · 26 weeks
- NCT01753362LIRAGLUTIDE IN OVERWEIGHT PATIENTS WITH TYPE 1 DIABETES2012 · 85 randomized · 26 weeks
- ELEGANTThe Effect of Liraglutide on Insulin-associated wEight GAiN in Patients With Type 2 Diabetes Mellitus (ELEGANT Trial)2012 · 50 randomized · 26 weeks
- S0030942011 · 12 weeks
- NCT01455441Does the GLP-1 Receptor Agonist (Victoza®) Improve the Metabolic Response to Physical Training in Patients With Type 2 Diabetes?2011 · 36 randomized · 16 weeks
- NCT01911468Short-term Combined Treatment With Liraglutide and Metformin Leads to Significant Weight Loss in Obese Women With Polycystic Ovary Syndrome and Previous Poor Response to Metformin2011 · 40 randomized · 12 weeks
- NCT01272232Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: A 56 Week Randomised, Double-blind, Placebo-controlled, Three Armed Parallel Group, Multi-centre, Multinational Trial With a 12 Week Observational Follow-up Period2011 · 846 randomized · 56 weeks
- S0030722011 · 122 randomized · 12 weeks
- S0030752011 · 52 randomized · 52 weeks
- NCT01272219Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Trial With Stratification of Subject to Either 56 or 160 Weeks of Treatment Based on Pre-diabetes Status at Randomisation2011 · 3,731 randomized · 56 weeks
- NCT01296412A Phase III, Multicenter, Randomized, Open-label Clinical Trial Comparing the Efficacy and Safety of a Sitagliptin-Based Treatment Paradigm to a Liraglutide-Based Treatment Paradigm in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Monotherapy2011 · 653 randomized · 26 weeks
- NCT01029886Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes and Inadequate Glycemic Control Treated With Lifestyle Modification and Oral Antidiabetic Medications2010 · 912 randomized · 26 weeks
- NCT01175473An Open-label, Randomized Two-arm Parallel Group Study to Compare the Effects of 4-week QD Treatment With Lixisenatide or Liraglutide on the Postprandial Plasma Glucose in Patients With Type 2 Diabetes Not Adequately Controlled With Metformin2010 · 148 randomized · 4 weeks
- S0030712010 · 99 randomized · 24 weeks
- NCT01784965Addition of a Glucagon-like Peptide-1 to a Calorie Restricted Diet Augments Weight Loss and Decreases Risk of Type 2 Diabetes and Cardiovascular Disease.2009 · 68 randomized · 14 weeks
- NCT00781937Effect of Liraglutide on Long-term Weight Maintenance and Additional Weight Loss Induced by a 4 to 12 Week Low Calorie Diet in Obese Subjects; A 56 Week Randomised, Double-blind, Placebo Controlled, Parallel Group, Multicentre Trial With a 12 Week Follow-up Period2008 · 422 randomized · 56 weeks
- NCT00700817The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Subjects With Type 2 Diabetes. A 26-week, Randomised, Open-label, Active Comparator, Three-armed, Parallel-group, Multi-centre, Multinational Trial With a 52-week Extension2008 · 665 randomized · 26 weeks
- LEAD-6Effect of Liraglutide or Exenatide Added to a Background Treatment of Metformin, Sulphonylurea or a Combination of Both on Glycaemic Control in Subjects With Type 2 Diabetes2007 · 464 randomized · 26 weeks
- NCT00422058Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes: A 20-week Randomised, Double-blind, Placebo-controlled, Six Armed Parallel Group, Multi-centre, Multinational Trial With an Open Label Orlistat Comparator Arm and With an 84-week Extension Period2007 · 564 randomized · 52 weeks
- S0030672007 · 564 randomized · 52 weeks
- LEAD-1Liraglutide Effect and Action in Diabetes (LEAD-1): Effect on Glycaemic Control After Once Daily Administration of Liraglutide in Combination With Glimepiride Versus Glimepiride Monotherapy Versus Glimepiride and Rosiglitazone Combination Therapy in Subjects With Type 2 Diabetes.2006 · 1,041 randomized · 26 weeks
- NCT00393718Effect of Liraglutide on Glycaemic Control in Subjects With Type 2 Diabetes2006 · 411 randomized · 52 weeks
- LEAD-5Liraglutide Effect and Action in Diabetes (LEAD-5): Effect on Glycaemic Control After Once Daily Administration of Liraglutide in Combination With Glimepiride and Metformin Versus Glimepiride and Metformin Combination Therapy, and Versus Insulin Glargine Added to Glimepiride and Metformin Combination Therapy in Subjects With Type 2 Diabetes.A Six-month Randomised, Double-blind, Parallel-group, Multi-centre, Multi-national Trial With an Open-label Treat-to-target Insulin Glargine Control Arm.2006 · 581 randomized · 26 weeks
- NCT00395746Effect of Liraglutide in Combination With Sulfonylurea (SU) on Glycaemic Control in Subjects With Type 2 Diabetes2006 · 267 randomized · 52 weeks
- LEAD-2Liraglutide Effect and Action in Diabetes (LEAD-2): Effect on Glycaemic Control After Once Daily Administration of Liraglutide in Combination With Metformin Versus Metformin Monotherapy Versus Metformin and Glimepiride Combination Therapy in Subjects With Type 2 Diabetes2006 · 1,091 randomized · 26 weeks